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a b s t r a c t
This consensus statement addresses the current three main modalities of treatment of homozygous
familial hypercholesterolaemia (HoFH): pharmacotherapy, lipoprotein (Lp) apheresis and liver trans-
plantation. HoFH may cause very premature atheromatous arterial disease and death, despite treatment
with Lp apheresis combined with statin, ezetimibe and bile acid sequestrants. Two new classes of drug,
effective in lowering cholesterol in HoFH, are now licensed in the United Kingdom. Lomitapide is
restricted to use in HoFH but, may cause fatty liver and is very expensive. PCSK9 inhibitors are quite
effective in receptor defective HoFH, are safe and are less expensive. Lower treatment targets for lipid
lowering in HoFH, in line with those for the general FH population, have been proposed to improve
cardiovascular outcomes. HEART UK presents a strategy combining Lp apheresis with pharmacological
treatment to achieve these targets in the United Kingdom (UK). Improved provision of Lp apheresis by
use of existing infrastructure for extracorporeal treatments such as renal dialysis is promoted. The
clinical management of adults and children with HoFH including advice on pregnancy and contraception
are addressed. A premise of the HEART UK strategy is that the risk of early use of drug treatments beyond
their licensed age restriction may be balanced against risks of liver transplantation or ineffective
treatment in severely affected patients. This may be of interest beyond the UK.
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1. Aim
This is a consensus statement by HEART UK (Hyperlipidaemia
Education and Atherosclerosis Research Trust United Kingdom) on
a strategy for managing homozygous familial hyper-
cholesterolaemia (HoFH) in the UK and treating to the lower lipid
targets suggested by the European Atherosclerosis Society (EAS)
(Table 1) [1], which are the same as those applying to heterozygous
familial hypercholesterolaemia (HeFH). It aims to provide
consensus advice on the use of the three main modalities of
treatment: pharmacotherapy, lipoprotein (Lp) apheresis and liver
transplantation. Better treatment from birth [2] has the potential to
greatly improve life expectancy n this condition. This is not inten-
ded as a didactic statement but aims to provoke discussion, form
opinion and inform commissioners of healthcare and clinicians.
This may be of interest outside the UK, particularly as the avail-
ability in Europe of lomitapide (see below), a proven effective but
expensive cholesterol lowering therapy pharmacotherapy for
HoFH, is under question [3].
2. Background
Familial hypercholesterolaemia (FH) is an inherited cause of
very high serum cholesterol, present from birth, due to mutations
affecting low density lipoprotein receptor (LDLR) activity. The
prevalence of HoFH in the UK, based on the prevalence of hetero-
zygotes of 1 in 500, is 1 in a million. Family grouping and consan-
guinity may result in local increases in prevalence. Some countries
appear to have a higher prevalence [4,5] but diagnostic criteria vary.
Prevalence in the UK and elsewhere may be underestimated
because of hitherto unsuspected phenotypic variation [6]. The
presence of two mutant alleles in HoFH typically raises blood
cholesterol level to 4 times the age and gender related mean. Lack
of LDLR activity in the liver reduces removal of low density lipo-
protein cholesterol (LDLC) from the blood [7]. About 90% of cases
are caused by mutations in LDLR [8,9] and the rest by mutations in
genes affecting at least 3 other proteins [8]: apolipoprotein B
(APOB) which is the main ligand for the LDLR, Proprotein Con-
vertase Subtilisin/Kexin type 9 (PCSK9), which reduces the recy-
cling of LDL receptor and LDLR adaptor protein (LDLRAP1), which
facilitates LDLR function. PCSK9 mutations causing hyper-
cholesterolaemia are due to gain of function, all the others cause
loss of function of the gene product due to qualitative or quanti-
tative defects [10,11]. Bi-allelic mutations of the LDLRAP1 gene
cause Autosomal Recessive Hypercholesterolaemia (ARH) in
contrast to the much more common Autosomal Dominant Hyper-
cholesterolaemia (ADH), which results from bi-allelic mutations in
the other genes.
Lp apheresis physically removes LDL particles and is an estab-
lished, safe and effective treatment for HoFH in the UK but access
needs to be improved. Its availability worldwide is variable [12].
Established cholesterol lowering drugs act principally by up-regu-
lating LDLR activity. Their effectiveness in HoFH is largely deter-
mined by residual LDLR activity [13]. Lomitapide and two PCSK9
inhibiting drugs, evolucomab and alirocumab, have recently been
approved by the European Medicines Agency (EMA). Lomitapide
[14] is a small molecule inhibitor of microsomal triglyceride
transfer protein. It reduces the hepatic assembly of very lowdensity
lipoprotein (VLDL) and intestinal chylomicrons and consequently
reduces LDL-C production, an action independent of LDLR activity.
Mipomersen [15], a second generation antisense oligonucleotide,
which inhibits hepatic APOB synthesis has a similar effect but is not
licensed by the EMA. Evolocumab and alirocumab are monoclonal
antibody inhibitors of PCSK9 protein [16], which reduce LDLR
catabolism and their effectiveness is determined by LDLR activity.
HEART UK considers these PCSK9 inhibitors to be equivalent.
Options for treatment of HoFH also include liver transplantation
[17,18] and have included portacaval shunting [19]. Liver trans-
plantation for HoFH is uncommon in Europe and the UK, as dis-
cussed below, but is more common in some countries, possibly
reﬂecting lack of alternatives or their cost. Portacaval shunting is
now obsolete due to inconsistent cholesterol lowering and un-
wanted effects [20] and is not considered as an option in this
statement.
There is a dilemma in themanagement of very young children in
that treatment, including liver transplantation [21], has to begin
early in life [22] to prevent serious and irreversible aortic and
coronary arterial disease. However, clinical trial evidence of treat-
ment in this age group is lacking. The question of whether liver
transplantation in children offers better lifetime beneﬁt than
apheresis combined with pharmacotherapy remains unanswered
[23]. There is good evidence of the safety of Lp apheresis in children
but trials of lomitapide are restricted to adults over 18 years old and
evolocumab to children over 12 years old. This consensus state-
ment by HEART UK outlines a management strategy for HoFH
combining Lp apheresis with lomitapide and PCSK9 inhibitionwith
consideration of treatment of severely affected children and young
adults. It is limited only to pharmacotherapy licensed for lowering
LDL-C in HoFH. Our approach is to keep the choice of modality of
treatment open and under continuous review for each patient and
to support an interim strategy for clinical management of HoFH
pending further trials. Priority is given to the early use of apheresis
on the grounds of known efﬁcacy and safety. Weekly rather than
fortnightly apheresis is promoted as a means of more effective LDL-
C lowering. A justiﬁcation is given for more frequent apheresis
based on the kinetics of the post-apheresis rebound. The need for
greater availability of apheresis, in support of this strategy, is
highlighted. A premise of the HEART UK clinical strategy for man-
aging HoFH is that the early use of lomitapide and/or evolocumab,
beyond their current licensed age restriction, in severely affected
children and young adults should be balanced against the risks of
liver transplantation [24].
3. Diagnosis of HoFH
Due to its hitherto unsuspected phenotypic variability, diagnosis
of HoFH should not rely exclusively on LDL-C [25]. LDL-C, clinical
evaluation, family history of CVD and genetic testing contribute to
the accuracy of diagnosis. Each parent, necessarily, carries at least
one allele causing FH. Diagnostic criteria for HoFH [1] are shown in
Table 2. HoFH is likely if LDL-C > 11mmol/L in children aged under
18 and > 13 mmol/L in adults before treatment. However, a recent
study of 167 patients aged 1 to 75, with a genetic diagnosis of HoFH
participating in therapeutic trials, showed untreated LDL-C ranging
from 4.4 to 27.2 mmol/L [6]. Hypertriglyceridaemia reduces the
predictive accuracy of LDL-C for HoFH. Cutaneous and tendon
xanthomata developing before the age of 10, evidence of cardio-
vascular disease (CVD) and family history of premature CVD sup-
port the diagnosis and should raise suspicion with less severely
elevated cholesterol values. Corneal arcus is suggestive in children
and young adults, particularly if aged under10. HoFH should be
Table 1
Lipoprotein targets.
LDL-C mmol/L Non-HDL-C mmol/L
Adults >18 <2.5 <3.3
Adults with CVD <1.8 <2.6
Children <3.5 <4.3
Targets apply to the interval mean. For patients on Lp apheresis techniques lowering
HDL-C only LDL-C should be used.
M. France et al. / Atherosclerosis 255 (2016) 128e139 129
suspected in children if both parents have HeFH. The deﬁnition of
HoFH in this statement includes ADH due to compound heterozy-
gotes, double heterozygotes (digenic) and true homozygotes
causing ARH. The genetic background determines LDLR activity,
response to pharmacotherapy and the severity of disease. The
presence of mutations affecting APOB and LDLRAP1 have a more
favourable prognosis than those affecting LDLR or PCSK9 [8]. Re-
ceptor negative patients with ADH have the worst prognosis [26].
About three quarters of patients are receptor defective (residual
LDLR activity (2e25%) and the rest are receptor negative (LDLR
activity <2%) [27]. In a study of heterozygous familial hyper-
cholesterolaemia (HeFH) in a French population [28], the contri-
bution of known genes was LDLR, 91%, APOB, 8% and gain of
function PCSK9, 1%. Based on these gene frequencies the expected
gene composition in the HoFH population is: LDLR true homozy-
gotes and compound heterozygotes combined, 90%, LDLR and APOB
digenic heterozygotes, 8%, LDLR and PCSK9 digenic heterozygotes,
1.0%, APOB homozygotes 0.7%, PCSK9 digenic heterozygotes,1% and
PCSK9 homozygotes 0.01%. ARH is very rare. PCSK9 mutations
therefore occur in about 1% of this population. In a Dutch popula-
tion [29] reported gene frequencies were LDLR, 95% and APOB, 5%
with no gain of function PCSK9 discovered and in the UK LDL-R, 93%,
APOB about 5% and gain of function PCSK9 1.7% [30]. Although the
presence of a gain of function PCSK9 allele, which increases PCSK9
levels, in HoFH predicts a good response to PCSK9 inhibitors,
response in the HoFH population is mainly determined by residual
receptor activity [31]. The functional status of many variants is
currently unknown but receptor negative patients do not respond
to PSCK9 inhibitors [31].
Mutation analysis should be done by comprehensive DNA
sequencing of introns and exons of the LDLR, APOB, PCSK9 and
LDLRAP1 gene loci by an accredited laboratory. There are over 1900
[32,33] known allelic variants for the LDLR gene. Testing residual
receptor activity would be very useful but is not generally available.
High LDL-C in the range of HoFH with development of tendon and
cutaneous xanthomata before the age of 10 years should be classed
as HoFH even in absence of two known mutations. Failure to
discover amutationwhere there is a high clinical suspicion of HoFH
may be due to mutations in novel genes, rare uncharacterised al-
leles of genes known to cause ADH or polygenic hyper-
cholesterolaemia. A high LDL-C gene score, based on the number of
single nucleotide polymorphisms (SNP) known to be associated
with hypercholesterolaemia, suggests a polygenic rather than a
monogenic cause [30,34]. Xanthomata also occur in sitosterolaemia
[35], which has a similar clinical presentation [36] and lysosomal
acid lipase deﬁciency [37,38], although this has distinguishing
features.
4. Statement 1: diagnosis of HoFH
a. Patients with suspected HoFH should undergo genetic testing as
this is useful for risk stratiﬁcation and in the case of receptor
negative patients predicts lack of response to drug treatment.
b. Full informed consent should be obtained, which should include
counselling on the possibility of a negative test or variation of
unknown signiﬁcance.
c. Mutation analysis should be by comprehensive DNA sequencing
of introns and exons of the LDLR, APOB, PCSK9 and LDLRAP1 gene
loci in an accredited laboratory.
d. A clinical diagnosis of HoFH should not be rejected if no muta-
tion is found and sitosterolaemia has been excluded.
e. Where no mutation is found a high LDL-C gene score supports a
polygenic rather than monogenic aetiology.
f. Fasting samples should be used at diagnosis to assess triglyc-
eride levels and permit calculation of LDL-C. Indicative LDL-C
levels are >11.0 mmol/L in children (aged under 18) and >13
mmol/L in adults. Lower levels should not be discounted if
clinical suspicion is high.
g. HoFH should be suspected if both parents have HeFH where the
risk is 1 in 4.
h. Once a diagnosis of HoFH is conﬁrmed, siblings should be
screened as each has a 1 in 4 chance of having the condition and
a 1 in 2 chance of having HeFH.
5. Clinical management of HoFH
In HoFH, very premature life threatening asymptomatic coro-
nary arterial disease develops. Atheroma of the aortic root associ-
ated with aortic valve ﬁbrosis, which may threaten the coronary
ostia [39], may develop before the age of 5 (see management of
children below). Referral to a cardiologist, for initial assessment, is
recommended because of the rapidly evolving technology for non-
invasive assessment of coronary arterial disease [40]. It should be
explained to patients that there are limitations to non-invasive
techniques and that angiography may be required for full
assessment.
Cardiovascular risk factors, other than as described in this
statement for lipids and aspirin, use, should be managed in accor-
dancewith UK National Guidelines. The overall beneﬁt versus harm
of aspirin use in the general population is not proven for primary
prevention of cardiovascular disease but is supported by meta-
analysis for secondary prevention from the age of 16 years [41]. In
patients with HoFH over 16 years old, who have not had a cardio-
vascular event, net beneﬁt of aspirin is a reasonable assumption
because atheromatous disease is inevitable. Separate recommen-
dations aremade for children younger than 16 years old (see below)
because of fewer years of exposure to high cholesterol and the
heterogeneity of the condition.
6. Statement 2: clinical management of adults (>18) with
HoFH
a. All patients should be referred to a cardiologist at diagnosis.
b. Coronary and carotid arterial disease should be assessed at
diagnosis with full investigation as appropriate.
Table 2
Clinical and genetic diagnostic criteria for HoFH.
Presence of 2 disease causing alleles affecting introns and exons of the LDLR, APOB, PCSK9 and LDLRAP1 gene loci
Or
LDL-C >11.0mmol/L in childrenwith tendon or cutaneous xanthomata before age 10 or 13.0mmol/L in adults with clinically obvious tendon or cutaneous xanthomata. But
because of the now recognized genetic and clinical heterogeneity of HoFH, lower LDL-C does not exclude HoFH. Genetic diagnosis, supplementary to clinical assessment
including cholesterol, is preferred.
Or
Qualifying cholesterol level and both parents with genetically conﬁrmed HeFH
LDLR, low density lipoprotein receptor; APOB, apolopoprotein B; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLRAP1, low density lipoprotein receptor adaptor
protein 1 gene loci.
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c. The gradient across the aortic valve and root should be
evaluated by echocardiography at presentation and annually.
d. There should be a clinical assessment for cardiovascular
disease every 6 months and immediate investigation if car-
diovascular symptoms develop.
e. New onset or worsening angina or its equivalents such as
breathlessness, easy fatigue, tachyarrhythmia or postural
syncope, which may indicate aortic stenosis, should prompt
early referral to a cardiologist.
f. Flexible open access arrangements are needed to discuss
cardiovascular symptoms and treatment problems. Patients
should be encouraged to exercise and be taught to recognize
“red ﬂag” symptoms of cardiovascular disease.
g. Patients should be counselled about the possibility of an
acute coronary event and how to identify it and told to dial
999 if necessary.
h. Cardiovascular disease, blood pressure, weight, diet, exercise,
smoking and alcohol use should be assessed 6 monthly.
Treatment response may need to be assessed more
frequently if there is progression of cardiovascular disease.
i. Other than lipid management and the use of aspirin
addressed in this statement cardiovascular risk management
should be in accordance with UK National Guidelines [42].
j. Oral aspirin, 75mg once a day, to prevent atherothrombosis,
should be considered from the age of 16 years (see section on
children).
k. Non-invasive testing for asymptomatic cardiac ischaemia
should be considered every ﬁve years or for evaluation of
symptoms as required. Computer tomography coronary
angiography and cardiac magnetic resonance imaging are
preferred, if available, to stress testing such as stress echo-
cardiography [43].
l. The lipid team should be involved if patients are admitted to
hospital for any reason. An alert card with contact details
should be issued.
m. Patients should be under the long term supervision of a
lipidologist experienced in managing HoFH.
7. Lipoprotein targets in HoFH
LDL-C lowering is the principal target for drug treatment of
HoFH. Treatment targets for LDL-C, following an EAS consensus [1],
are based on meta-analysis of efﬁcacy and safety [44e46]. HoFH
falls into the category of highest risk. Equivalent non-HDL choles-
terol (non-HDL-C) targets may be calculated by the addition of 0.78
mmol/L (30 mg/dl) to LDL-C [42,47] as an allowance for cholesterol
in triglyceride rich particles. LDL-C and non-HDL-C targets are
shown in Table 1. There is no ideal, practical lipid measure for
monitoring apheresis. APOB measurement may have advantages
[48] but APOB in VLDL rebounds more quickly than APOB in LDL.
Direct measurement of LDL-C is not widely available. Calculation of
LDL-C involves assumptions about lipoprotein composition, which
may not be correct following apheresis. HDL-C may be temporarily
low following apheresis and since it is subtracted from total
cholesterol to calculate both LDL-C and non-HDL-C, these will be
overestimated. These considerations probably are only relevant in
the ﬁrst few days following apheresis. Weekly and longer post-
apheresis values for LDL-C and non-HDL-C should not be affected.
Pragmatically, calculated LDL-C and non-HDL-C are acceptable to
monitor apheresis. Values of these different lipid measurements
should occupy the same centile in normal population distributions
in order to be equivalent [49]. Interconversion of LDL-C and non-
HDL-C is problematic because the conversion factor increases with
lower LDL-C and increasing triglyceride concentrations, reﬂecting
the lower proportion of LDL-C in non-HDL-C [50]. Therefore, non-
HDL cholesterol should bemeasured but not inferred. A strategy for
combining Lp apheresis with pharmacological treatment to achieve
target lipid levels is illustrated in Fig. 1.
Gene association [51] and prospective studies [52] have estab-
lished lipoprotein (a) (Lp(a) as an independent cardiovascular risk
factor. Lp(a) above 500 mg/L (125 nmol/L), measured using an
isoform independent assay [53], is an independent CVD risk factor
in HeFH and levels increase with gene dose [54]. However, there is
no published evidence that Lp(a) is a risk factor in HoFH, where the
effect of markedly raised LDL-C may overwhelm other factors. This
view is supported by a post hoc analysis of a retrospective follow of
CVD in 44 genetically characterised FH homozygotes [55], which
showed that neither raised Lp(a) normale gender increased the risk
of CVD. However, Lp(a) might increase risk in homozygotes with
LDL levels in the heterozygotes' range, either through the mild
nature of the causal mutations or consequent on statin therapy,
which lowers LDL but not Lp(a). Lp apheresis, lomitapide [56],
evolocumab [57] and alirocumab [58] all lower Lp(a). However,
priority should be given to LDL-C lowering to target values. Lp(a)
should be measured pre-treatment by an isoform independent
assay to allow further study of its signiﬁcance in HoFH.
8. Statement 3: lipoprotein targets in HoFH
a. LDL-C lowering is a proxy for clinical effectiveness.
b. Target values for treatment should be the same as for HeFH
(Table 1).
c. Calculated LDL-C expressed as the interval mean (see below
under Lp apheresis) should be used as the lipid lowering target
for patients treated by Lp apheresis.
d. Non-HDL cholesterol may be used but should be measured and
not inferred from LDL-C. The measure may be unreliable
immediately after apheresis, especially with double membrane
ﬁltration, which markedly reduces HDL-C.
e. A “lower the better” approach is advocated to try to achieve EAS
targets for LDL-C.
f. Lp(a) is not a treatment target as priority is given to LDL-C
(except as discussed above).
9. Lp apheresis
Lp apheresis physically removes LDL and VLDL and other
atherogenic lipoprotein particles including Lp(a) [59]. It is estab-
lished as a safe and effective ﬁrst line treatment for HoFH in adults
and children [13,60e66]. The commonest problems are related to
complications of vascular access but anaemia due to iron deﬁciency
is relatively common. A toolkit for setting up an Lp apheresis ser-
vice has been produced by HEART UK [67]. A register of existing
providers of Lp apheresis is kept by HEART UK [68]. Commercial
systems have similar effectiveness and their technical speciﬁca-
tions have been reviewed recently [65,66,69]. In HoFH, 1e2 plasma
volumes need to be treated ideally at weekly intervals. However,
due to resource constraints and its inconvenience, Lp apheresis is
usually performed every two weeks in the UK. An acute 65e70%
[70] reduction of LDL-C is established as the UK standard for per-
formance of Lp apheresis but is intermittent. Treatment targets for
cholesterol apply to the interval mean, which can be estimated
using the modiﬁed Kroon equation [70,71]. More effective LDL-C
lowering drug treatment may have the beneﬁt of allowing less
frequent apheresis. However the frequency of apheresis is an
important determinant of the average LDL-C because of the kinetics
of LDL-C rebound.
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10. Kinetics of LDL-C lowering
The interval mean LDL-C calculated using the Kroon [72] equa-
tion modiﬁed [70] for HoFH as:
LDL-C interval mean ¼ a LDL-C immediately pre-apheresis þ (1-a) LDL-C
immediately post-apheresis, where a ¼ 0.65
The rebound of LDL-C following apheresis is determined by
constant LDL-C production rate and a constant fractional catabolic
rate (1st order kinetics). The fractional catabolic rate, k, in HoFH is
about 10% per day [73]. Rebound of 50% will occur after 6.9 (0.693/
k) days, 75% at 13 (1.3/k) days and 90% at 23 (2.3/k) days. Provided
that the LDL-C is not allowed to rebound completely 70% reduction
of the pre-apheresis LDL-C will lower the post-apheresis baseline
Fig. 1. Management of HoFH to new lipid treatment targets.
Table 3
Predicted LDL-C interval mean from a maximum of 13.0 mmol/L, achieved by regular Lp apheresis reducing the pre-apheresis LDL-C by 70%, at different intervals.
Apheresis cycle LDL-C rebound at 3.5 days (interval
mean) mmol/L
LDL-C rebound at 7 days (interval
mean) mmol/L
LDL-C rebound at 14 days (interval
mean) mmol/L
1 6.6 (5.6) 8.5 (6.7) 10.8 (8.4)
2 5.3 (4.1) 7.8 (6.0) 10.6 (8.0)
3 5.0 (3.8) 7.7 (5.8) 10.6 (8.0)
4 5.0 (3.7) 7.7 (5.8) 10.6 (8.0)
See text for calculation of interval mean.
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and the LDL-Cwill rebound to a slightly lower ﬁgure before the next
apheresis. A constant value for post-apheresis is established after
about 4 cycles. The shorter the interval between apheresis the
greater will be the LDL-C lowering.
The rebound concentration at any time period following
apheresis can be calculated as:
LDL-C t ¼ LDL-C maximum e (LDL-C maximum e LDL-C immediately post-
apheresis)ekt
Where LDL-C is the LDL-C at time t days post-apheresis, the
maximum LDL-C is the plateau concentration after apheresis when
production equals removal and k is the fractional catabolic rate
(about 0.1). Table 3 shows illustrative LDL-C achieved with regular
apheresis at 14, 7 and between 3 and 4 days. This is the basis for our
recommendation to promote weekly apheresis or even twice a
week in exceptional circumstances such as pregnancy, as, because
statin and other pharmacotherapy cannot be used, the rebound is
more rapid [74].
Good vascular access is essential to allow efﬁcient processing of
an adequate plasma volume. However, anecdotally, among our
centres in the UK, arteriovenous ﬁstulae seem to be more prob-
lematic in Lp apheresis than in haemodialysis. The reasons remain
to be deﬁned. Vein to vein access is preferredwherever possible but
early referral to create a ﬁstula should be made if vascular access is
difﬁcult, to avoid unnecessary damage to the blood vessels. There is
a need for research into improved techniques for vascular access,
particularly in children.
11. Statement 4: standards for an apheresis service in the UK
a. The lead clinician should be an expert in lipidology and the
treatment should be carried out primarily by specialist nurses.
b. The unit could be embedded with other specialist units such as
haematology or a dialysis unit.
c. Standards should accord with those produced by HEART UK.
d. Apheresis should be provided at weekly intervals unless target
LDL-C concentration can be achieved with a lower frequency
and adjuvant drug treatment.
e. More frequent treatment, even for short periods, may be
considered in exceptional circumstances such as pregnancy.
f. Vein to vein access is preferred and should be used wherever
possible but early referral to create a ﬁstula should be made if
access becomes difﬁcult.
g. LDL-C lowering should accord with current EAS guidelines.
h. Patients should be regularly reviewed in a multi-disciplinary
team meeting.
i. Response to treatment and general medical issues should be
discussed at least 6 monthly.
j. Patients should be entered onto the UK apheresis registry run
jointly by HEART UK and The Royal College of Physicians.
12. Access to Lp apheresis in the UK
There are signiﬁcant gaps in the provision of Lp apheresis ser-
vice in the UK mainly in Scotland, Northern Ireland, the North East,
East Anglia and Cornwall and Devon. New centres in these areas
should be established to avoid excessive travelling. Existing ser-
vices for Lp apheresis could support new centres on a hub and
spoke model. NHS Blood and Transplant [75] and equivalent bodies
in the devolved nations offer a range of extra-corporeal therapies
and could support Lp apheresis across the UK. Commercial com-
panies also manage an extensive network of facilities providing a
range of extra corporeal treatments and could accommodate Lp
apheresis even on the small scale required for patients with HoFH.
Expertise in lipidology is already sufﬁciently devolved to supervise
treatment of HoFH provided more widely in the UK. More
comprehensive coverage across the UK would encourage weekly
rather than fortnightly Lp apheresis. Plasmapheresis is morewidely
available than Lp apheresis and may be used if Lp apheresis is not
available. Lp apheresis is preferred because it is more selective.
13. Statement 5: availability of Lp apheresis in the UK
a. Gaps in the distribution of services should be addressed to
facilitate weekly apheresis.
b. There exists a wide infrastructure providing extra-corporeal
therapies across the UK and these could be exploited to improve
the availability of Lp apheresis.
c. Lp apheresis is preferred but plasmapheresis remains an option.
14. Standard drug treatment combined with apheresis for
patients with HoFH
Combined treatment with rosuvastatin or atorvastatin [76] with
ezetimibe [77] may lower cholesterol by up to 40% in HoFH [25,76]
in patients treated by apheresis. There are no trials of BAS in HoFH
but a therapeutic trial is reasonable. Survival analysis in patients
with HoFH before and after the introduction of statins showed
beneﬁt measured as risk of death or time to a major adverse car-
diovascular event MACE [78].
15. Statement 6: standard drug treatment
a. All patients should be offered maximum doses of atorvastatin or
rosuvastatin combined with ezetimibe. Other statins may be
tried in the event of intolerance
b. BASmay be useful in pregnancy. Colesevelam has the advantage
of improved glycaemic control in type 2 diabetes [79,80] and
improved tolerability.
16. PCSK9 inhibitors
PCSK9 protein is increased in familial hypercholesterolaemia,
being highest in HoFH, and also by HMG CoA reductase inhibitor
(statin) treatment, explaining the synergy between PCSK9 inhibi-
tion and statins [81]. Evolocumab is licensed from the age of 12.
Alirocumab has no license for treatment of HoFH. Evolocumab is
self-administered by subcutaneous injection using a spring loaded
device every 2 or 4 weeks. Phase 3 trials demonstrate safety
[82,83]. Response to evolucomab in 50 HoFH patients not on
apheresis depended on LDLR activity and was ineffective in its
absence [31]. Responses in patients with receptor defective HoFH
even with the same mutation are surprisingly variable [84] with
reductions ranging from 7% to 56%, suggesting that unless patients
are known to be receptor negative a therapeutic trial is worthwhile.
The TAUSSIG trial [85], a long term open label study of treatment of
HoFH patients, with evolucomab has accumulated experience in
106 patients, including 14 adolescents, with planned 5 years of
follow-up. LDL-C lowering was inﬂuenced by genotype. Mean re-
ductions were 24% for LDLR defective, 6% for LDLR negative/
negative, 51% for PCSK9 gain of function/LDLR negative and 43%
for ARH. Although trough levels of evolucomab were reduced
following apheresis there remained full suppression of PCSK9.
Evolucomab was similarly effective in patients on apheresis or not.
The plasma half-life of evolocumab is between 11 and 17 days and
was unaffected by apheresis in the TAUSSIG study but might be
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affected by more frequent apheresis. There is now considerable
accumulated experience with evolucomab but there remains some
concern about adverse neurocognitive effects and need for
continued pharmacovigilance [86].
17. Statement 7: treatment of HoFH with evolocumab
a. All HoFH patients on apheresis and standard drug treatment
with LDLC above target, who are receptor defective, should have
a trial of treatment with evolocumab.
b. Homozygotes or compound heterozygotes with gain of function
PCSK9 alleles or double heterozygotes with, for example, an
LDLR defective allele and a gain of function PCSK9 allele
(digenic) are likely to respond well to PCSK9 inhibition.
c. Patients who respond with 10e15% reduction in LDL-C (or in-
terval mean LDL-C if on Lp apheresis) should continue
treatment.
d. Evolocumab should be injected subcutaneously directly after
apheresis.
18. Lomitapide treatment for HoFH
Lomitapide is equally effective in adults with or without Lp
apheresis treatment, with a mean 40%e50% [56] LDL-C reduction.
However, there is considerable inter-individual variability in
response [87,88] from no response to over 90% [89]. This may be
partly attributed to genetic variability in the target microsomal
triglyceride transfer protein [90]. The lipid lowering effects of
lomitapide are not affected by Lp apheresis [91]. In phase 3 studies
with extended follow up, against a background of Lp apheresis and
standard drug treatment, up to 74% achieved LDL-C <2.5 mmol/L
and 58% < 1.8 mmol/L [92]. This demonstrates the feasibility of
achieving EAS targets in HoFH. Lomitapide is subject to a Risk
Evaluation and Mitigation Strategy (REMS) [93] (Table 4) due to its
predictable effects on hepatic fat accumulation, intestinal fat and
fat soluble vitamin absorption. Patients should take daily supple-
ments containing at least 400 international units of vitamin E, 200
mg of linoleic acid, 210 mg alpha-linolenic acid, 110 mg eicosa-
pentaenoic acid and 80 mg docosahexaenoic acid. Careful dose
escalation reduces the incidence of side effects, which are more
common at higher doses. Account should be taken of concomitant
use of cytochrome P450 3A4 inhibitors according to manufacturer's
instructions. Current versions of manufacturer's instructions
should be consulted. The Lomitapide Observational Worldwide
Evaluation Registry (LOWER) has been established to monitor long
term safety in clinical practice [94].
19. Statement 8: treatment of HoFH with lomitapide
a. Lomitapide should be considered for adults with HoFH, who
have failed to achieve treatment targets while on apheresis and
standard drug treatment and have had a trial of evolocumab.
b. The frequency of Lp apheresis may be reduced when combined
with lomitapide and/or evolocumab.
20. Pregnancy in patients with HoFH
Pregnancy is hazardous for patients with HoFH. Lp apheresis
during pregnancy is safe [95]. The risks of lipid lowering drug treat-
ment in pregnancy are unknown. Bile acid sequestrants (BAS) with
folate supplements are safe but effectiveness is uncertain. A clinical
trial (NCT02399839) isaddressingtheeffectof lomitapideexposureat
conception andduring pregnancyonmajor congenital abnormalities.
More effective treatment from an early agewill make pregnancy
in HoFH less hazardous. Genetic testing of the partner is desirable
to exclude HeFH, especially in cultures where ﬁrst cousin marriage
is more common.
21. Statement 9: pregnancy in patients with HoFH
a. Patients should be advised that pregnancy in HoFH is hazardous.
b. As a favourable outcome is uncertain, decision making should
follow the principles of co-production [96] with joint decision
making.
c. Pre-conception, women should be referred to a cardiologist. The
pressure gradient across the aortic valve and root should be
assessed by echocardiography.
d. Pre-conception, women with HoFH should be counselled that
their children will have HeFH and if their partner has HeFH the
risk of HoFH is 1 in 2.
e. Women should be offered twice weekly LDL apheresis during
pregnancy, if practicable, when pre-treatment LDL-C is partic-
ularly high, the LDL-C lowering during the procedure is less than
desirable (target 70% acute reduction) or there is evidence of
progression of cardiovascular disease.
f. Careful monitoring and treatment of anaemia is essential.
g. Drug treatment, other than BAS with folate supplementation
should not be used as evidence of safety is lacking.
22. Advice on contraception and hormone replacement
treatment for patients with HoFH
Risks andbeneﬁts of contraceptionneed tobebalanced. Stopping
lipid lowering drugs for an uncertain period pre-conception is
particularly hazardous inHoFH. The thrombotic risk associatedwith
hormonal contraceptive methods should be carefully assessed.
Combined preparations, particularly third generation preparations
should be avoided [97,98]. Up to date advice is available from The
Faculty of Sexual and ReproductiveHealthcare under the auspices of
the Royal College of Obstetrics andGynaecologyandNICE [99]. Risks
and beneﬁts of hormone replacement treatment (HRT) should be
discussedwithwomenwith postmenopausal symptoms. Parenteral
preparations have the lowest thrombotic risk.
23. Statement 10: advice on contraception and HRT for
patients with HoFH
a. Non-hormonal techniques for contraception are recommended.
If essential, oral contraceptives with the lowest thrombotic risk
should be selected.
Table 4
Risk Evaluation and Mitigation Strategy (REMS) for lomitapide.
 Need for close monitoring of liver function tests and liver fat accumulation
 Restriction of use to patients accepting a low fat diet (20% of energy as fat) and restriction of alcohol use
 Fat soluble vitamin supplementation
 Baseline assessment of liver disease and regular frequent monitoring as indicated in product labelling
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b. Survival into the menopause is uncommon at the moment but
improved survival is expected. HRT is not an absolute contra-
indication because post-menopausal symptoms may be severe
and debilitating in some women.
c. Risks of HRT should be discussed.
d. HRT for relief of postmenopausal symptoms should be in the
form of parenteral preparations, which have the lowest
thrombotic risk.
24. Treatment of children with HoFH and licensing of new
drugs
Atheromatous CVD develops in children with HoFH despite
apheresis and conventional treatment. Aortic root atheroma is
more common in children starting apheresis from the age of 10
rather than 5 and is an important cause of morbidity [100]. High
priority should be given to the prevention of aortic and supra-
valvular aortic disease as damage is irreversible due to ﬁbrosis,
even with subsequent effective cholesterol lowering treatment.
There is, therefore, a need for early effective treatment of children
[101]. The treatment volume required for Lp apheresis in children is
based on weight and safety has been established over a 21 year
follow up [102]. There is little or no data on the optimum means of
vascular access in very young children. Atorvastatin, rosuvastatin,
simvastatin, ﬂuvastatin and ezetimibe are licensed for use in chil-
dren over 10 years old. Pravastatin is licensed from the age of 8. BAS
other than colesevelam are licensed from the age of age 6. The
TESLA Part B study of evolucomab included patients with HoFH
from the age of 12 [84]. The TAUSSIG study, which included 14
adolescents, showed equivalent response compared with adults.
The study is planned to extend to 5 years. Evolocumab is licensed
from the age of 12 years. The HAUSER randomised controlled trial
(NCT02392559) of evolocumab is recruiting children aged 10e17
with heterozygous familial hypercholesterolaemia and is designed
to evaluate LDL-C lowering and safety. It is due to report in 2017. A
single arm open label trial of lomitapide in childrenwith HoFH aged
5e18 has been agreed by the EMA (EMA/PDCO/49561/2015) and is
due to start in 2016.
Liver transplantation has been used in the past and there have
been recent technical advances [18]. Data from the European Liver
Transplant Registry indicate that 21 liver transplants were done in
Europe, including the UK, between 1988 and 2009 for HoFH re-
cipients [103]. The population of Europe in 2009 was 743 million.
Assuming a prevalence of 1 in a million fewer than 3% of HoFH
patients were treated in this way. However, it may be more prev-
alent in other places. A series of 36 cases in Iran [104], where
apheresis is not widely available has recently been published and
there are several recent case descriptions of successful outcome
[105e107]. The genetic and clinical heterogeneity of HoFH is now
recognized and should determine the clinical management. In the
UK, HoFH has a low priority rating for liver transplant but there is
an option of lobar transplant [108e110] from a living related donor
even if the donor is a heterozygote [111]. Because of limited organ
availability, operative risk and problems of lifelong immunosup-
pression, liver transplant combined with heart transplantation
should remain a therapeutic option for severely affected children
and young adults with HoFH, as a last resort [17].
Atheromatous cardiovascular disease is rare in children without
HoFH and there is no evidence to support the use of aspirin to
prevent atherothrombosis. However, aspirin is commonly and
safely used for other thrombotic conditions [112e114]. The pres-
ence of atheromatous disease and therefore the likely beneﬁt of
aspirin cannot be assumed, as we have for adults, due to fewer
years of exposure to raised cholesterol and the clinical
heterogeneity of HoFH. Aspirin should only be considered if there is
evidence of atheromatous disease. Doses should be at the low end
of the dose range, 1e5 mg/Kg/day [115,116], recommended for
arterial thrombotic disease in children. The anti-platelet response
to aspirin should be conﬁrmed [117]. Aspirin should be dis-
continued in febrile children, especially with ﬂu like symptoms and
chicken pox, to minimise the small risk of Reye's syndrome.
25. Statement 11: the treatment of children
a. Children should be seen in an appropriate environment. Parents
should be involved and educated and genetically counselled.
Family clinics are encouraged and transition to adult clinics
should be planned from age of 14e16 and transfer arranged
between 16 and 18 years.
b. Treatment should be initiated by a paediatrician with expertise
in the management of HoFH.
c. Lp apheresis should be started as soon as possible but it is
difﬁcult to get children aged younger than 5 to accept the pro-
cedure. It should be considered from the age of 2 and started
before the age of 7.
d. Lp apheresis combined with statin and ezetimibe at licensed
doses should be instituted as early as possible. BAS treatment
may be tried but discontinued if ineffective.
e. Evolocumab should be considered from the age of 12 if treat-
ment targets are not achieved.
f. Lomitapide should be considered from the age of 18 if treatment
targets are not achieved.
g. Earlier treatment should be considered if evidence of athero-
sclerosis is seen, particularly when threatening the coronary
ostia. Coronary angiography, performed by a paediatric cardi-
ologist with expertise in HoFH, is preferred to stress testing in
severely affected children.
h. Low dose aspirin, 1e5 mg/Kg/day up to 75 mg, should be
considered if atheromatous disease is evident. Response to
aspirin should be assessed and the lowest effective dose used.
Aspirin should be discontinued during febrile illness.
i. Prescription of drugs beyond licence should follow the princi-
ples of co-production, preferably in the context of a multidis-
ciplinary team meeting. Risk may be balanced against the
beneﬁt of avoiding aortic arch surgery or the risk of liver
transplantation, which might be considered as a last resort if
there has been suboptimal achievement of therapeutic target
lipid levels in severely affected children.
j. Portacaval shunt as a treatment for HoFH is now obsolete.
26. Commissioning treatment for HoFH in the UK
HoFH is a rare disease with estimates of prevalence in Europe
ranging from 1 in 75,000 (Denmark) [4], 1 in 300,000 (Netherlands)
[5] and 1 in a million in the UK. Although diagnostic methods differ,
these estimates show that HoFH is considerably rarer than the
deﬁnitionof a rarediseaseused in theDepartmentofHealthStrategy
for Rare Diseases [118] of 1 in 2000. HeFH, untreated, is associated
with premature cardiovascular disease and occurs in 1 in 500 of the
UK population but is effectively treated with statins. As described
above HoFH is much more severe then HeFH and statins are rela-
tively ineffective. Effective treatment of HoFH with Lp apheresis,
evolocumab and lomitapide is expensive per patient but the beneﬁt
is largewith the possibility of a normal life expectancy. Because of its
severity and its rarity, HEART UK supports the classiﬁcation of HoFH
as a rare diseasewithin the UK strategy. There are approximately 80
casesofHoFH in theUKcomparedwithup to8000casesof other rare
diseases. This statement by HEART UK fulﬁls the requirement of the
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strategy for a clearly deﬁned care pathway in the UK including
diagnosis, cascade screening and lifetime care.
The disastrously accelerated premature development of
atheroma in HoFH has so far precluded randomised controlled
trials of LDL-C lowering. However, a rationale for treatment of HoFH
is provided by the huge body of data, including a meta-analysis of
LDL-C lowering [46,119e123] and a Mendelian randomisation
study [124], showing that reduction of CVD events relates to the
extent of LDL-C lowering regardless of the mechanism. The best
available data on the cardiovascular risk associated with HoFH on
standard drug treatment and the potential beneﬁt of further
cholesterol reduction come from a trial of Mipomersen [125,126]. In
a group of patients with FH including about half with HoFH, car-
diovascular risk expressed as MACE/1000 patient months was 25.7
on standard treatment before mipomersen compared with 3.6 after
[126]. Temporal advances in lipid lowering treatment of HoFH,
including Lp apheresis, have improved survival and reduced
adverse cardiovascular events [127].
The rarity of HoFH and its severity require special consideration
of risk and beneﬁt of treatment, especially for children. Commis-
sioning of treatment for HoFH in the UK is the responsibility of NHS
England and equivalent bodies in the devolved nations. Lomitapide
is expensive for individual patients but there are only around 80
people in the UK with HoFH. The cost effectiveness of LDL-C
lowering treatment is greatest when absolute cardiovascular risk
and LDL-C are high, HoFH being an extreme case and is a function of
absolute LDL-C reduction. The “number needed to treat” (NNT)
[128] based on absolute CVD risk reduction is a useful comparator
of cost-effectiveness [129]. Cholesterol lowering to new targets
should markedly improve prognosis, particularly if started early in
life. Evolocumab is licensed for lipid lowering in the general pop-
ulation and is consequently signiﬁcantly cheaper than lomitapide.
Cost effectiveness analysis of treatment of HoFH is complicated by
the lack of controlled trials. However, in contradistinction from
cholesterol lowering in the none-HoFH population, it is likely that
every individual patient with HoFH will beneﬁt clinically from
cholesterol lowering in proportion to its degree i.e. NNTclose to 1. A
useful analogy would be, for example, antibiotic use where the NNT
is close to 1. Very effective treatments are in the range 2e4. This
concept may be applied to the effectiveness of treatment in
achieving EAS targets for LDL-C [130] where the NNT to achieve
<2.5 mmol/or <1.8 mmol/L are 2 and 4 respectively. Thus
achievement of EAS targets can be achieved, even with mono-
therapy with lomitapide, in a substantial proportion of patients.
27. Statement 12: commissioning treatment for HoFH in the
UK
a. HoFH should be adopted as a rare disease within the UK strategy
for rare diseases.
b. Lp apheresis and treatment with lomitapide and evolocumab
should be commissioned as a package to allow optimal and cost
effective combination treatment.
c. Estimation of treatment cost effectiveness should take into ac-
count total cardiovascular risk, the baseline LDL-C and its ab-
solute reduction and the number needed to treat, especially
when considering the incremental beneﬁt of new treatments.
d. In children, the presence of atheromatous disease in anatomi-
cally critical sites should be taken into account when judging the
risks, beneﬁts and cost of early drug treatment.
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